Dichloroacetate (DCA) is an investigational drug targeting the glycolytic hallmark of cancer by inhibiting pyruvate dehydrogenase kinases (PDK). It is metabolized by GSTZ1, which has common polymorphisms altering enzyme or promoter activity.
| INTRODUC TI ON
Deregulated energetics is an established hallmark of cancer that includes the glycolytic phenotype (elevated glucose uptake and glycolysis, with conversion of pyruvate to lactate in the presence of adequate oxygen). 1, 2 The glycolytic phenotype is widespread amongst many cancer types, and is exploited clinically in imaging of cancers with [ 18 F]-fluorodeoxyglucose positron emission tomography ( 18 F-FDG PET). 2, 3 Dichloroacetate (DCA) is an established investigational drug that can target the deregulated energetics of cancer.
DCA reverses the glycolytic phenotype, redirecting the metabolism of pyruvate away from lactate production and into mitochondrial oxidation. 4, 5 It does this through the inhibition of pyruvate dehydrogenase (PDH) kinases (PDKs) http://www.guide topha rmaco logy. org/GRAC/Famil yDisp layFo rward ?famil yId=608, a family of four kinases (PDK1-4) that phosphorylate and inactivate PDH. 5 Antitumor activity in vivo was first demonstrated in lung and breast cancer models, 6, 7 and has subsequently been shown in a range of solid tumor types (reviewed in 4 ). The actions of DCA include inhibiting proliferation, inducing apoptosis, enhancing apoptosis of other cytotoxic agents (particularly those that target mitochondrial metabolism [8] [9] [10] [11] ), and inhibiting angiogenesis, through mechanisms including decreasing the mitochondrial membrane potential, increasing p53 activity, decreasing hypoxia inducible factor-1α expression, and decreased VEGF expression. 4 With decades of clinical use in adults and children with congenital lactic acidosis, 12, 13 DCA has progressed rapidly into clinical trials against cancer, resulting in four published reports on phase I/II trials in solid tumors. [14] [15] [16] [17] Chu et al 14 concluded the recommended phase 2 dose (RP2D) for oral DCA is 6.25 mg/kg b.i.d., based on the maximum tolerated dose, with peripheral neuropathy (PN) arising after one or more months of treatment being one of the most common concerns, however, high variability in pharmacokinetics and the occurrence of neuropathy was observed among patients. 14 The previous DCA trials in cancer included limited drug serum concentration monitoring, thus it remains unclear whether the RP2D is adequate for efficacy in the cancer setting. Further, it was noted in two of the trials 16, 17 that it took several weeks for DCA to become detectable in serum, suggesting a loading dose may be of value. Thus, an effective dosing regimen of DCA for the treatment of cancer patients has not been established. An expected effective concentration of DCA can be proposed based on its ability to inhibit the PDKs in vitro. DCA is a pan-PDK inhibitor, with the constitutive isoform, PDK2, having the lowest IC 50 (0.2 mmol/L), whereas PDK1 and PDK3 require considerably more DCA for inhibition (1.0 mmol/L and 8.0 mmol/L, respectively). 5, 18 PDK1 and PDK3 are both target genes of the transcription factor hypoxia inducible factor (HIF), and so may be expressed at elevated levels in hypoxic regions of solid cancers. 5 DCA is metabolized primarily in the liver by glutathione transferase Zeta (GSTZ1). The GSTZ1 gene has three common nonsynonymous single nucleotide polymorphisms (SNPs) resulting in four common isoforms of the protein 19, 20 and one rare isoform. 21 The four main isoforms have been characterized in vitro for activity with haloacids, with GSTZ1*A» GSTZ1*B ~ GSTZ1*C > GSTZ1*D for activity toward DCA. 19, 20 GSTZ1 also has polymorphisms in the promoter, including SNP rs7160195 at nt −1002, which impact on the level of expression of luciferase reporter constructs, 22 and may alter the level of enzyme expression in the liver. 23 A luciferase reporter promoter construct containing the −1002G vs −1002A allele resulted in approximately sixfold higher promoter activity when tested in transiently transfected HepG2 cells (figure 5B in 22 ). Consistent with this, expression of GSTZ1 in frozen human liver samples, estimated by both protein and mRNA-based methods, was found to be approximately threefold higher in Caucasians who did not carry the −1002A allele (figures 1 and 3 in 23 ). It should be noted that these associations are not necessarily true in African-Americans, where different haplotypes are present. 22, 23 The impact of the genetic variants of GSTZ1 on DCA kinetics and dynamics in patients has been reported in only a small number of individuals, and in only one of the cancer clinical trials, 15 but has led to the development of a test to enable geneticbased dosing for DCA. 24 In addition to genetic polymorphisms influencing DCA pharmacokinetics, DCA is an inhibitor of its own metabolism, irreversibly inhibiting GSTZ1 activity and leading to degradation of the protein, 25, 26 explaining why subsequent doses of DCA have a longer half-life compared to the initial dose. 27 This adds complexity in understanding when DCA might achieve steady-state concentrations during multiple dosing, requiring pharmacokinetic investigations on multiple days. Furthermore, giving a loading dose to achieve steadystate concentrations more rapidly may be a useful strategy.
Multiple myeloma (MM) is a plasma cell malignancy affecting bone marrow and lytic lesions in the bones that remains incurable despite improvements in therapy including cyclophosphamide-bortezomib-dexamethasone (CyBorD or CVD), lenalidomide/ thalidomide, melphalan, and autologous stem cell transplantation. 28, 29 Poor prognostic variants are often related to clonal genetic aberrations including 1p-and t(4,14) amongst others. 30, 31 MM is associated with expression of a clonal immunoglobulin protein (paraprotein or Mband) that is used routinely to monitor disease and assess response to therapy. The importance of metabolism changes has only recently been appreciated in hematological cancers. 32 The metabolic phenotype of myeloma includes the glycolytic phenotype, present in approximately 50% of MM cell lines examined, 33, 34 with high lactate dehydrogenase (LDH) and PDK1 expression associated with poorer patient outcomes 33 and drug resistance, which may be overcome by reversing the glycolytic phenotype. 35, 36 DCA combined with
K E Y W O R D S
Chemotherapy, clinical pharmacology, drug metabolism, genetic polymorphism, toxicology bortezomib showed additive cytotoxic effects in vitro and improved outcomes in a mouse model. 34 Most recently, lactate has been identified as a survival factor, 37 and inhibition of lactate transporters (MCTs) could reduce cell viability. 37, 38 Extrapolating from these observations of the glycolytic phenotype, MM patients may be good candidates to benefit from DCA treatment.
In this study, we designed the DiCAM (DiChloroAcetate in Myeloma) clinical trial to improve upon previous trials.
Pharmacogenetics were examined in both the acute and chronic treatment settings. The spectrum of cancer types treated with DCA was expanded into hematological malignancies, and MM patients were chosen allowing easy monitoring of disease via blood paraprotein levels. The MM patients were in plateau phase and in relatively good health, increasing the likelihood of them completing the treatment regimen and giving reliable pharmacokinetic information. Existing PN was not an exclusion criteria so that the significance of this potential side effect could be examined in a real patient setting. A loading dose of DCA was included to take advantage of the inhibition of GSTZ1, which was predicted to lead to more rapid achievement of therapeutic concentrations. While conducted in a limited number of patients, this study has been able to provide valuable insights for improved future trial design for testing efficacy of DCA in cancer patients. 
| MATERIAL S AND ME THODS

| Patient Eligibility
Patients were eligible for inclusion if they had: plasma cell myeloma in plateau phase (defined as neither progression nor response for at least 28 days); no change in myeloma therapy for at least 16 weeks International Myeloma Working Group (IMWG) to include an increase in the paraprotein by ≥25% and at least 5g/L, or >25% increase in difference between involved and uninvolved light chain level, with an absolute increase of >0.1g/L. Response was defined as at least an IMWG minimal response, including a reduction in the paraprotein by ≥25%. 39 In the case of light chain only myeloma, a modified criteria of a 25% decrease in the difference between the involved and uninvolved light chains and an absolute reduction of at least 100 mg/L was chosen as a minimal response criteria is not available for light chain only myeloma. 
| Study Design
| Drug formulation and dosing
Clinical grade crystalline sodium DCA (TCI America, Portland, OR) was purchased and compounded into 500 mg, 125 mg, and
mg gelatine capsules with inert filler by Capital Compounding
Pharmacists (Woden, ACT, Australia). Capsules were prepared as patients were recruited, stored by The Canberra Hospital Oncology Pharmacy, and dispensed within 6 months of compounding. Patients received five doses of 25 mg/kg over days 1-3: dose 1 in the morning of d1, then 25 mg/kg b.i.d. on d2 and 3. From d4 onwards, the dose was 6.25 mg/kg b.i.d., with the exception of d8, when a single dose of 25 mg/kg was given in the morning, to replicate the pharmacokinetic measurements of d1. DCA treatment was in addition to other maintenance treatments and was continued for 12 weeks, at which time DCA was discontinued.
| Monitoring of patient residual disease and DCA toxicity
A physical examination including Total Neuropathy Score (TNSc), 40 blood counts, serum biochemistry tests were undertaken at baseline and repeated on day 8, 28, 56, 84, 112 (4 months), 168 (6 months), and 252 (9 months) of the trial. Paraprotein level and/or free light chain levels were measured at baseline and days 28, 56, 84, 112, 168, and 252. Patients were withdrawn for new onset or progression to Grade-3 peripheral neuropathy (defined as any of the seven aspects of TNSc having a score > 3), or any other emergent grade 3 or 4 toxicity if the symptoms were not alleviated after supportive treatments.
| Patient serum pharmacokinetic sampling
Measurements of serum DCA concentrations were made for determination of pharmacokinetics of DCA on d1 and d8 of the study. Blood samples were collected at time 0, 1, 2, 3, 4, 5, 6, and 24 hours after administration of DCA. For ongoing monitoring of DCA concentrations, the original protocol onto which P001 was recruited collected through samples only on d28, d56, and d84. This was revised for the subsequent patients to include collection of trough and peak concentrations as follows: On d15 and d22, blood samples were taken before DCA administration to measure maintenance dose trough concentration. On d28, d56, and d84, blood samples were taken before and 2 hours after DCA administration to monitor the maintenance dose trough concentration and peak concentration.
| DNA isolation, genotyping, and haplotype analysis
DNA was extracted from peripheral blood (QIAGEN blood kit, Cat.
No.51106) and GSTZ1 genotyping was performed by published methods for SNPs in the promoter (nt −1002, rs7160195) and in protein-coding exons (nt 94, rs3177427; nt 124, rs7972; and nt 245, rs1046428).
Haplotypes were inferred from those present in the Australian European population studied previously. 19, 20 The expected proteins are described with the standard nomenclature for glutathione transferases. 41 
| Analysis of serum DCA concentrations
Serum DCA concentrations were analyzed in duplicate by liquid chromatography-mass spectrometry (LC-MS) for patients P001-P004, and by gas chromatography-mass spectrometry (GC-MS) for patients P005-P007. Prism 7 was used to calculate the area under the plasma concentration curve (AUC) on d1 from 0-6 hours and the half-life of DCA (using a nonlinear regression, one phase decay curve fit) from drug concentrations on d1 from peak (at 1 or 2 hours) to 6 hours (See Appendix S1 for details.)
| In vitro drug combination studies
The MM cell lines RPMI 8226, U266, NCI-H929, MM.1S, and MM.1R 
| RE SULTS
| Patient characteristics
Six Caucasian patients were enrolled in this study between May 2015 and June 2016. Patient demographics, baseline disease, prior treatments, and comorbidities are listed in Table 1 . Four of these six patients had myeloma with intact paraproteins, whereas two patients had free light chain myeloma (P001, free kappa; P002 free lambda).
The mean age at enrollment was 65.6 years (range 52-77). They had 2-7 prior therapies. Five of six patients were on comaintenance treatments during the study (Table 1) . Maintenance treatment in P002 (CyBorD) was stopped at study d30 due to steroid myopathy and insomnia.
Four patients had normal cytogenetics and one patient was untested (Table 1) . Patient P004 had confirmed complex cytogenetics including chromosome 1 abnormalities, 14q32 rearrangements and monosomy 13 which are associated with poor prognosis. 30, 31 P004
was withdrawn from the study after 1 month due to rapid disease progression.
| Patient response
One of the six patients (P002) showed a response to DCA treatment at d28 maintained to d84 ( Figure 1A , Figure S1 ). Two patients had transient falls in measurable disease at d28 (P001 and P003), but did not meet response criteria. After DCA treatment was completed, P002 steadily progressed. P004 was taken off the trial at d28 due to disease progression. P005 had a 25% (1g) increase in paraprotein on d56, which did not meet criteria for progression and returned to the baseline level (4 g/L) and remained at that level throughout the rest of the trial. P006 had a gradual increase in paraprotein during the trial, reaching the criteria for disease progression on d84, the last day of DCA treatment ( Figure 1A, Figure S1 ).
| Toxicity
No patient withdrew from the trial due to DCA induced toxicity, and none required dose reduction during the 3-month DCA treatment period. Blood counts, liver, and kidney function were not adversely affected, consistent with previous findings from DCA trials in cancer patients. 14, 15, 17 There were no problems with compliance as indicated by interviewing the patients and return of unused medication.
Five of six patients started the trial with some PN from previous myeloma treatments, and five of six patients experienced some small increase in TNSc while on DCA, but the TNSc decreased after completing DCA treatment, indicating the PN induced by DCA was reversible ( Figure 1B) . On the last day of treatment (d84), P002 presented with a significant increase in TNSc, with both the strength and motor symptoms having a score of 3 ( Figure S2 ). This made his TNSc much higher than the other patients ( Figure 1B ), but as with the milder changes in the other patients, the symptoms gradually abated over the 6 months of monitoring after the DCA treatment was completed.
| Pharmacokinetics
Serum DCA concentrations were determined on d1 and d8 of the trial after a single oral dose of 25 mg/kg taken at approximately 9 am. Patients were not given special breakfast instructions, which may contribute to variation in absorption rates and peak concentrations. The effect of food on DCA absorption has not been studied; published pharmacokinetic studies have always been done in initially fasting subjects. On d1, serum DCA concentrations peaked rapidly in all patients (median peak time 1 hour, mean peak concentration 0.33 mmol/L, range 0.15-0.68 mmol/L, Figure 2A ). DCA was then cleared with a mean half-life of 93 min (Table 2) , with 90% of the drug being cleared by 6 hours, and DCA being undetectable at 24 hours (Figure 2A) . Notably, P001 and P007 had faster apparent clearance of DCA compared to other patients (CL/F > 65 L/h, Table 2 ). This was also reflected in a smaller AUC ( Table 2 ) and a sharp drop in DCA concentrations between 1 and 2 hours (Figure 2A) . On d8 of the study (Figure 2B Figure 3A , Table S1 ). This trough concentration range is very similar to the data reported by Chu et al. 14 Strikingly, P002 had DCA trough concentrations two-to threefold higher than the average of the other patients on d56 and d84 ( Figure 3A , Table S2 ), correlating with the highest TNSc ( Figure 1B) . Neither neuropathy score nor trough concentrations were elevated during the first month of DCA treatment.
The DCA peak concentrations ranged from 0.04 to 0.69 mmol/L when patients were on maintenance dose ( Figure 3B , Table S1 ).
| Pharmacogenetics
We determined the genotypes of the patients for the common promoter and coding region SNPs of GSTZ1. Overall, the alleles present in our seven patients were consistent with expected frequencies for Caucasians. Notably, P001 and P007 possessed one allele of GSTZ1*A, a minor haplotype with 3.6-fold enzymatic activity toward DCA in vitro compared to wild-type protein. 20 The presence of GSTZ1*A correlated with the shorter half-life of DCA and lower AUC on d1 (Figure 2A , Table 2 ).
All isoforms of GSTZ1 are irreversibly inactivated by DCA requiring expression of new protein to restore enzyme activity. Promoter SNPs have been described that result in expression differences of GSTZ1. An A at nt −1002 is associated with lower promoter activity in vitro 22 and lower protein expression in human liver. 23 P002 possessed an uncommon genotype at nt −1002, being homozygous A for the low activity promoter. This correlated with the highest average DCA trough concentration (Figure 3 , Table 2 ) and the highest TNSc ( Figure 1B ).
TA B L E 1 Patient characteristics
| Drug combinations in vitro
We examined the effect of DCA in combination with CyBorD on cell viability of myeloma cell lines in vitro. A fixed ratio of the cytotoxic agents (400: 1: 10, based on P002's CyBorD dosing regimen) for cyclophosphamide: bortezomib: dexamethasone (DEX) was tested against U266 and RPMI 8226 cells, which have previously been shown to have different levels of glycolytic activity. 34 Consistent with Sanchez et al, 34 Figure 4C) . Similarly, when DCA was added the combination of LEN and DEX, there was no difference in total viable cell number ( Figure 4D) . A similar lack of synergistic effect of DCA with these agents was observed in the additional myeloma cell lines MM.1S and MM.1R which were sensitive to LEN ( Figure S3 ).
| D ISCUSS I ON
Targeting the cancer metabolic phenotype may offer a novel cancer treatment strategy not yet in routine clinical use. The glycolytic phenotype has received much interest, as it can be targeted by DCA, a prototypic pan-PDK inhibitor that has been in clinical use for other indications for decades. 4 In this small pilot study we found F I G U R E 1 (A) Patient disease outcomes. Paraprotein level or FLC levels were measured at screening, and then on 28, 56, 84, 112, 168, and 252 of study. Patient disease readout was normalized to the baseline disease level on screening day (100%). DCA treatment period is indicated by the green bar. Graphs of raw readouts for each patient are included in Figure S1. (B) Patient Total Neuropathy Scores (TNSc). The neuropathy of each patient was assessed through seven components, as described in the methods. Graphs detailing the seven component scores for each patient are included in Figure S2 . DCA treatment period is indicated by the green bar PN being the primary concern. 14-17 In this study, we too found that PN was the only significant side effect, seen only after chronic use and was reversible. Five of six patients entered the trial with some preexisting PN, which was not greatly exacerbated by DCA at 6.25 mg/kg b.i.d., thus DCA can be used in patients with existing peripheral neuropathy. Table S1 Bold indicates the unusual values and genotypes discussed in the text.
F I G U R E 3 Patient serum DCA (A) trough and (B) peak concentrations over 12 weeks of the trial. Serum was collected before (trough) and 2 h after (peak) the morning oral maintenance dose of 6.25 mg/kg. Full details of values and variations in data points collected for each patient are included in Table S1 . (Note: Peak concentration samples were not collected under the original protocol onto which P001 was recruited.)
Significant DCA-related PN was only experienced in one patient, P002 ( Figure 1B ) in association with higher trough DCA concentrations ( Figure 3A) and an uncommon GSTZ1 genotype -homozygosity for the −1002A promoter SNP ( Table 2 ). The −1002A promoter allele has been demonstrated to have reduced activity in vitro. 22 We propose that during chronic DCA treatment, when GSTZ1 is persistently inactivated and degraded, −1002A/A individuals will reexpress GSTZ1 protein at a lower rate or level making them more susceptible to chronic accumulation of DCA and thus PN. This reduced ability to re-express the protein may be more important in determining DCA kinetics and side effects than the activity (ie, protein haplotype) of the enzyme toward DCA.
In Caucasians, −1002A is in dis-equilibrium with E32K 23 (ie, Heterozygosity for −1002A in P001 did not associate with unusual peak or trough DCA concentrations, suggesting that homozygosity is necessary for the phenotype to be significant. The −1002A SNP has a population frequency of 0.33 in Australian Europeans, 22 which would result in homozygotes constituting 11% of the population.
In addition to having the highest total neuropathy score, P002
also demonstrated the strongest reduction in disease in response to DCA treatment, maintaining a response until the end of the treatment period ( Figure 1A ). This may be attributed to the high drug concentrations experienced by P002 compared to the other patients.
The alternative explanation of a combination effect of DCA with
CyBortD was explored in vitro, but no synergism was demonstrated.
Thus, both the response and increased toxicity are attributable to altered drug concentrations due to underlying genetic polymorphisms.
The pharmacokinetics on d1 after the initial high dose of DCA (acute treatment setting) showed an interesting correlation between the GSTZ1*A isoform and a reduced half-life/ smaller AUC (Table 2) for DCA. However, this phenotype may be of less importance in the setting of long term cancer treatment, as the difference between P001 and other patients with different GSTZ1 genotypes had disappeared after 1 week of treatment ( Figure 2B) , presumably due to inactivation of GSTZ1 protein by DCA. Considering the low frequency of homozygosity for the −1002A, the lack of difference between protein-coding variants after Previous trials of DCA in brain and solid cancers showed that DCA therapy was associated with disease stabilization in heavily pretreated patients. 14, 15 Similarly, our evidence of response is modest, with only one patient (P002) showing a response ( Figure 1A ).
The initial low disease burden in these patients ( (IC 50 0.2 mmol/L), whereas peak concentrations ranged from 0.15 to 0.48 mmol/L. While this peak concentration may inhibit both PDK2 and PDK4 (IC 50 0.5 mmol/L), it remains below the IC 50 for PDK1 (1.0 mmol/L) and PDK3 (8 mmol/L), which are likely to be induced in many cancer types. 5 For this reason, patient recruitment to this version of the trial protocol was stopped, and our investigations are continuing with a modified dosing regimen that aims to maintain higher concentrations of DCA as observed on d8, while avoiding the chronic side effects of DCA treatment.
These discussions are based on DCA as a single agent, however, DCA is most likely to be used in combination regimens. In our in vitro studies, we saw no indication of beneficial combination interactions between DCA and commonly used myeloma treatments (Figure 4 and Figure S3 ), however, DCA did not interfere with their efficacy.
Where DCA was effective alone, this effect was often additive with the other agents, particularly at low doses of the other agent. We cannot exclude the possibility of pharmacokinetic interactions between DCA and these drugs, as there are no published studies on this topic. However, based on our in vitro results, DCA may be most beneficial for myeloma patients where the cytotoxicity of the other drug is low (eg, Figure 4C ) or when the concentration of the cytotoxic agent is low between doses (eg, Figure 4A and B).
This study concludes that further study of DCA in myeloma is warranted in patients with a higher disease burden and in combination with other therapies. While the small number of patients does not allow firm conclusions to be drawn about associations between GSTZ1 genetics and pharmacokinetics or peripheral neuropathy, future studies should include GSTZ1 genotyping of promoter and protein-coding polymorphisms to address these questions in additional patients. Regardless of GSTZ1 genotypes, a dosing regime based on drug concentrations and biomarkers rather than maximum tolerated dose, that can achieve higher concentrations without peripheral neuropathy is likely to be needed to achieve maximum benefit from DCA in the treatment of cancer.
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